medRxiv preprint doi: https://doi.org/10.1101/2021.11.24.21266833; this version posted January 18, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

Large-scale seroepidemiology uncovers nephrological pathologies in people with tau autoimmunity

Authors:

Andreia D. Magalhães[1†], Marc Emmenegger[1&], Elena De Cecco[1], Manfredi Carta[1‡], Karl Frontzek[1§], Andra Chincisan[1‖], Jingjing Guo[1], Simone Hornemann[1*], Adriano Aguzzi[1*]

Affiliations:

[1]Institute of Neuropathology, University of Zurich; CH-8091 Zurich, Switzerland

[*]Correspondence: simone.hornemann@usz.ch and adriano.aguzzi@usz.ch

[†]Present address: Department of Neurology, Inselspital, Bern University Hospital; CH-3010 Bern, Switzerland

[&]Present address: Division of Medical Immunology, Department of Laboratory Medicine, University Hospital Basel; CH-4031 Basel, Switzerland

[‡]Present address: Institute of Neurology, University of Zurich; CH-8091 Zurich, Switzerland

[§]Present address: University College London, Institute of Neurology, Queen Square Brain Bank; WC1N 1PJ London, United Kingdom

[‖]Present address: Credit Suisse; CH-8001 Zurich, Switzerland

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2021.11.24.21266833; this version posted January 18, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

Abstract:

Importance: Intraneuronal aggregates of the microtubule-associated protein tau play a pivotal role in Alzheimer's disease and several other neurodegenerative syndromes. Anti-tau antibodies can reduce pathology in mouse models of neurodegeneration and are currently being tested in humans.

Objective: To evaluate the seroprevalence of natural anti-tau autoantibodies and their potential association with diseases.

Design: In a cross-sectional study, plasma samples from a randomized university hospital cohort and healthy blood donors, collected from 2017 to 2020, were screened for anti-MTBD-tau plasma IgG autoantibodies (ατ) in a miniaturized, high-throughput ELISA. Samples were included if basic demographic data was available and age was ≥18 years. Data analysis was performed from December 2017 to August 2024. Titers were defined as $-\log_{10}(EC_{50})$ values. Titers of ≥1.8 were classified as $\alpha\tau^{+}$.

Participants: Blood was obtained during routine clinical care from 32,291 patients admitted as inpatients or outpatients to any department of a university hospital, or from 8,206 healthy blood donors.

Results: High-titer $\alpha\tau^{+}$ samples were surprisingly prevalent, with hospital patients being three times more likely to be $\alpha\tau^{+}$ than healthy blood donors (4.8% vs 1.6%). ατ autoantibodies ligated selectively tau, inhibited tau aggregation in vitro, and interfered with tau detection in plasma samples. No association was found between ατ autoantibodies and neurologic disorders. Instead, tau autoreactivity showed a significant association with kidney and urinary disorders (adjusted risk ratio (RR) 1.27, 95% CI 1.10-1.45, P=0.001 and 1.40, 95% CI 1.20-1.63, P<0.001 respectively).

Conclusions and Relevance: While ατ autoimmunity was not associated with neurologic diseases, its association with extraneural pathologies will require scrutiny in the context of anti-tau therapies. Moreover, immunochemical plasma tau assays were confounded by ατ antibodies, whose high prevalence may limit their usefulness as biomarker.

medRxiv preprint doi: https://doi.org/10.1101/2021.11.24.21266833; this version posted January 18, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

Main Text:

INTRODUCTION

Tau is a microtubule binding protein involved in cytoskeletal dynamics and expressed in neurons[1,2] and in extraneural tissues, including kidney.[2-5] It plays a pivotal role in Alzheimer's disease (AD),[6] and various syndromes collectively referred to as tauopathies.[7] The presence of brain neurofibrillary tau tangles correlates with cognitive decline,[8] and plasma measurements of total and phosphorylated tau have emerged as promising biomarkers for monitoring of AD progression.[9-12] Moreover, active and passive immunization with antibodies against different tau epitopes are being tested in clinical trials.[13]

Natural autoantibodies are generated against self-antigens in the absence of external antigen stimulation.[14] They are a normal part of the immunoglobulin repertoire and have physiological roles in homeostasis and surveillance,[15] but can also cause pathological autoimmunity. The study of natural autoantibodies can inform about properties of their targets, e.g. unrecognized protective or contributing roles in disease.[16] Some natural autoantibodies can even cause neurological disorders.[17,18,19]

Anti-tau autoantibodies have been detected in plasma of patients with AD[20] and Parkinson's disease,[21] but also in non-neurodegeneration controls.[22] The effects, if any, of natural anti-tau autoantibodies in modulating the risk of developing neurodegenerative diseases are unknown. The study of individuals with anti-tau autoantibodies could clarify their potential as modifiers or biomarkers of disease. Here, we tested 40,497 plasma samples from healthy blood donors and from patients admitted to a university hospital in a two-sites cross-sectional study for anti-tau immunoreactivity.

METHODS

Study design

From December 2017 until February 2020, residual heparin plasma samples were obtained from the Department of Clinical Chemistry, University Hospital of Zurich, USZ, Switzerland. Samples were collected during routine clinical care from patients admitted either as inpatients or outpatients (age ≥ 18 years) and were only included if basic demographic data was available, and an informed consent for research had been provided. From March until July 2020, EDTA plasma samples from blood donors were obtained from the Blood Donation Center of Zurich, Switzerland, according to

medRxiv preprint doi: https://doi.org/10.1101/2021.11.24.21266833; this version posted January 18, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

standard criteria of blood donation. Exclusion criteria were as reported.[23] Plasma samples were biobanked locally and tested in an automated indirect microELISA (Enzyme-Linked Immunosorbent Assay) for natural IgG autoantibodies against the microtubule-binding-domain of tau (MTBD-tau, tauK18,[23-25] and below). Demographic and clinical data for the hospital cohort was obtained from clinical records of the USZ with follow-up until December 2021, while detailed clinical data for the blood donor cohort were not available for this study. ICD-10 codes[26] were used for clinical data assessment. AD patients were selected using ICD-10 code F00 or G30. Non-neurodegeneration controls were defined by the lack of any Fxx or Gxx ICD-10 codes.

Automated microELISA screen

High-binding 1,536-well microplates (Perkin Elmer, SpectraPlate 1536 HB) were coated with 1 µg/mL of recombinant MTBD-tau (37 °C, 60 min; see eMethods in Supplement 1 for MTBD-tau production and purification). Plates were washed 3x with phosphate-buffered saline 0.1% Tween®20 (PBST) using a Biotek El406 washer-dispenser and blocked with 5% milk (Migros)-PBST (90 min). Plasma samples were diluted 1:20 in 1% milk-PBST and dispensed into the MTBD-tau-coated plates using ultrasound dispensing with an ECHO 555 Liquid Handler (Labcyte/Beckman Coulter). Each sample was tested at eight serial two-fold dilutions (1:50 to 1:6,000) using different volumes to a final volume of 3 µL/well. Human IgG-depleted serum (MyBioSource) was used as negative and anti-tau RD4 (4-repeat isoform) mouse monoclonal antibody[27] (05-804 clone 1E1/A6 Merck Millipore) as positive control. Plates were incubated (120 min, room temperature (RT)) and washed 5x with PBST. Secondary antibody peroxidase AffiniPure® goat anti-mouse IgG H+L (115-035-003, Jackson ImmunoResearch) at 1:2,000 dilution in 1% milk-PBST for the RD4 positive control, peroxidase AffiniPure® goat anti-human IgG Fcγ-specific (109-035-098, Jackson ImmunoResearch) 1:4,000 dilution in 1% milk-PBST for the plasma samples and the IgG-depleted serum negative control were dispensed into the plates using a Biotek MultifloFX dispenser. Plates were incubated (60 min, RT) and washed 3x with PBST. 3,3',5,5'-Tetramethylbenzidine (TMB) Chromogen Solution for ELISA (Invitrogen) was added as colorimetric horseradish peroxidase (HRP) substrate (3 min, RT). Finally, 0.5 M H_2SO_4 was added to stop the reaction. Plates were briefly centrifuged after each dispensing step except after dispensing of TMB. Plates were read at Optical Density (OD) = 450 nm in a plate reader (Perkin Elmer, Envision).

medRxiv preprint doi: https://doi.org/10.1101/2021.11.24.21266833; this version posted January 18, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

Competitive ELISA

High-binding 384-well plates (Perkin Elmer, SpectraPlate 384 HB) were coated with 4 µg/mL BT2 tau monoclonal antibody (#MN1010, Thermo Fisher) in PBS. Recombinant human tau^{441} (rPeptide) was diluted to a final concentration of 0.015 ng/mL and incubated with purified anti-tau autoantibodies (Supplement 1) four-fold serially diluted (1:1.66 to 1:106.6) in 1:2 plasma under rotation (500 rpm, 120 min, 37°C). Samples were transferred to BT2-coated plates and incubated (45 min, RT). After washing 4x with PBST, plates were incubated (0.125 µg/mL, 45 min, RT) with ab64193 (polyclonal IgG antibody; Abcam). Plates were washed 4x with PBST and incubated (1:2,000 dilution, 60 min, RT) with peroxidase AffiniPure® goat anti-Rabbit IgG (H+L) (111-035-045, Jackson ImmunoResearch). Plates were washed 4x with PBST and 1-Step™ Ultra TMB-ELISA solution (Thermo Fisher) was added (7 min, RT). After addition of 0.5 M H_2SO_4, plates were read at OD = 450 nm in a plate reader (Perkin Elmer, Envision).

Statistical analysis

Antibody titers were defined as the negative logarithm half-maximal responses ($-\log_{10}(EC_{50})$) obtained by fitting the OD = 450 nm of the eight dilution points of each sample tested in the micro-ELISA to a logistic regression fitter. We classified as positives samples with a cut-off of $-\log_{10}(EC_{50}) \geq 1.8$.[23] Non-informative samples (fitting error >20% $-\log_{10}(EC_{50})$ or high background) were excluded from the analysis.[23] In cases where more than one sample was available for the same individual the most recent $\log_{10}(EC_{50})$ value was used.

Age is presented as median with interquartile range (IQR) and comparisons were performed using non-parametric Mann-Whitney U test. Categorized age groups and sex of positives and negatives are shown as percentages and compared using two-proportions Z-test or χ^2 test for trend in proportions. Log-binomial regression models[28,29] using MTBD-tau autoreactivity were employed to estimate age-and-sex adjusted RRs (aRR) and 95% confidence intervals (CIs), and to investigate the association between the detection of anti-MTBD-tau IgG autoantibodies and different demographic features (Supplement 1).

Statistical significance was defined by 2-tailed P-value ≤ 0.05. Statistical analyses and data visualization were performed using R version 4.3.2 and RStudio version 1.4.1106.[30]

medRxiv preprint doi: https://doi.org/10.1101/2021.11.24.21266833; this version posted January 18, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

RESULTS

Prevalence of naturally occurring plasma anti-tau autoantibodies

We designed a cross-sectional study to investigate naturally occurring plasma IgG autoantibodies against MTBD-tau. Plasma samples from 32,291 university hospital patients (age ≥ 18 years) and 8,206 healthy blood donors were screened by miniaturized ELISA (Figure 1A).[23-25]

After exclusion of non-informative samples, 4.80% (n=1,169) of the 24,339 of hospital samples, but only 1.58% (n=104) of 6,590 healthy donors, were $\alpha\tau^+$ (Figure 1A-C). Hence, anti-tau immunoreactivity was more prevalent in unselected hospital patients than in healthy individuals (P<0.001). Demographic data was available for 4,157 of the 6,590 blood donors. Median ages were 42 (IQR 29-54) and 55 years (IQR: 40-69) for healthy donors and hospital patients, respectively (P<0.001). Of the healthy blood donors, 40.9% (n=1,698) were women, whereas for the hospital group, 47.7% (n=11,609) of the patients were women (P<0.001). Multivariate log-binomial regression[29,31] adjusted for age and sex showed that hospital patients had a 2.3x higher risk than healthy donors to be $\alpha\tau^+$ (aRR 2.30, 95%CI 1.83-2.92, P<0.001, Figure 1D).

The replicability of the microELISA screen was found to be high (R^2=0.84, P<0.001, Figure 1E). There was no cross-reactivity to two other proteins implicated in neurodegeneration, amyloid-ß pyroglutamate and the cellular prion protein (PrP^C).[24] Of 12,297 patient samples, 604 samples were positive against MTBD-tau and 5 against amyloid-ß pyroglutamate but none was cross-reactive against both targets (P=1, χ^2 test) (Figure 1F), Moreover, of 13,099 patient samples, 694 were reactive against MTBD-tau and 15 against PrP^C, but again none was cross-reactive against both targets (P=0.734, χ^2 test) (Figure 1G)

Specificity and biological activity of $\alpha\tau^+$ samples

To investigate their specificity, we purified anti-tau autoantibodies by MTBD-tau affinity chromatography from four individual $\alpha\tau^+$ patients (P1-P4) and from a pool of six $\alpha\tau^+$ sample (patient_IDs: J909190817, J802220975, J909190382, J90806029, J908060881 and J805040458). Purified anti-MTBD-tau autoantibody samples had EC_{50} values of 0.042-14.45 µg/ml whereas the mouse anti-MTBD-tau antibody RD4[27] had EC_{50}=0.002 µg/ml (eFigure 1A in Supplement 1). In a soluble-competition immunoassay (eFigure 1B, Supplement 1), purified $\alpha\tau^+$ autoantibodies showed a concentration-dependent binding to recombinant MTBD-tau purified by cation exchange and size exclusion chromatography and to a pool of 8 synthetic MTBD-tau peptides but not to albumin or an

medRxiv preprint doi: https://doi.org/10.1101/2021.11.24.21266833; this version posted January 18, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

unrelated synthetic peptide (eFigure 1C in Supplement 1). To probe for polyreactivity, purified $\alpha\tau^+$ autoantibodies were tested against several structurally unrelated autoantigens and bacterial proteins, including MTBD-tau, albumin, cardiolipin, DNA, insulin, and lipopolysaccharides (LPS). Anti-tau autoantibodies were reactive against MTBD-tau but not against any of the other antigens or uncoated plates (eFigure 1D in Supplement 1).

In immunofluorescent stainings, purified $\alpha\tau$ autoantibodies co-localized to cytoplasmic EGFP-0N4RTau in SH-SY5Y cells and showed similar binding patterns to an anti-tau mouse monoclonal antibody H7, but not to non-transfected cells (eFigure 1E in Supplement 1). On western blots, purified $\alpha\tau$ autoantibodies detected tau-specific bands in cell lysates of SH-SY5Y cells overexpressing $tau^{P301L/S320F}$, but not in parental (wt) SH-SY5Y cells (eFigures 1F and 2 in Supplement 1). Hence, the immunoreactivity of $\alpha\tau^+$ samples was highly specific for tau. All IgG subclasses and both κ and λ light chains were present in $\alpha\tau^+$ patients' samples (eFigure 1G and H in Supplement 1). Epitope mapping and light-chain typing revealed a polytypic response for 23% of the $\alpha\tau^+$ samples (eFigure 1H and I in Supplement 1).

To investigate whether purified $\alpha\tau^+$ autoantibodies interfere with the aggregation of MTBD-tau, samples from patients P7 and P8 were tested in an *in vitro* tau aggregation assay.[32] MTBD-tau aggregation was induced by heparin and shaking and monitored using Thioflavin T (ThT; eFigure 3, Supplement 1). The presence of $\alpha\tau^+$ autoantibodies reduced the plateau of the ThT fluorescence signal in the kinetic trace by about half, whereas antibodies purified by protein G affinity chromatography from an $\alpha\tau^-$ patient had no effect (eFigure 3, Supplement 1). Hence, $\alpha\tau^+$ autoantibodies inhibit MTBD-tau aggregation *in vitro*.

Plasma tau is a promising biomarker of progression for several neurological diseases.[9-12,33] We examined the effects of $\alpha\tau$ autoantibodies onto the performance of plasma tau immunoassays (Figure 2). Purified $\alpha\tau$ autoantibodies from 5 patients (P2-P6) were added to tau^{441}-spiked plasma. After incubation, the amount of free tau^{441} was analyzed by ELISA using commercial anti-tau antibodies for capture (BT2, epitope on human tau^{441}: residues 194-198) and detection (ab64193, epitope on non-phosphorylated and phosphorylated human tau^{441} surrounding residue 262).[34] Purified $\alpha\tau$ autoantibodies P4-P6 induced a concentration-dependent impairment of detection of tau^{441} hampering the detection of plasma-spiked tau^{441} by approximately tenfold at higher anti-MTBD-tau autoantibody concentration (Figure 2B, D). In contrast, P2-P3 did not show any significant impairment of the detection of plasma-spiked tau^{441}. This variability of interference is

medRxiv preprint doi: https://doi.org/10.1101/2021.11.24.21266833; this version posted January 18, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

explained by the binding epitopes on tau[441]. P4-P6 occupy tau residues 244 to 282 including the binding epitope of ab64193, whereas P2-P3 occupy residues 273 to 327 which are outside the epitope of ab64193 (eFigure 4 in Supplement 1). Hence, the presence of $\alpha\tau^+$ autoantibodies can interfere with the detection of plasma tau in immunoassays depending on the combination of epitopes of the patient samples and of commercial antibodies used in immunoassays.

Demographic characteristics of tau-immunoreactive patients

The age of $\alpha\tau^+$ patients (median: 58 years; IQR: 43-71) was significantly higher than that of $\alpha\tau^-$ (median: 55; IQR: 40-68; $P < 0.001$, Figure 3A). Univariate logistic regression analyses of health records for the 24,339 hospital patients showed that the prevalence of $\alpha\tau$ immunoreactivity increased with age, from 3.9% in patients aged <29 years to 7.6% in patients aged >90 years ($P<0.001$, Figure 3B). A log-binomial regression model[29,35] estimated that the RR for the presence of anti-MTBD-tau autoantibodies was highest for patients aged 70-99 years (RR 1.26, 95% CI 1.11-1.43, $P<0.001$, Figure 3C) and for women (RR 1.20, 95% CI 1.07-1.39, $P=0.002$, Figure 3C). Due to the association of anti-MTBD-tau autoantibodies with increased age and female sex, all further RRs were calculated using a multivariate log-binomial regression model adjusted for age and sex. To identify potential correlations between $\alpha\tau^+$ and specific diseases, we analyzed the admission to clinical departments. The highest RRs for $\alpha\tau^+$ were found for angiology (aRR 1.84, 95% CI 1.21-2.63, $P=0.002$) and nephrology (aRR 1.50, 95% CI 1.16-1.89, $P=0.001$, Figure 3D-E), whereas no significant difference was found between the percentage of $\alpha\tau^+$ and $\alpha\tau^-$ patients from the department of neurology (Figure 3D).

Neurological disorders and anti-tau autoimmunity

We next mined pseudonymized clinical diagnoses from the clinical records of the USZ pertaining to the diagnoses of 23,375 patients as represented by ICD-10 codes (Figure 4A). Given the involvement of tau in neurodegenerative diseases,[6] we focused on evaluating the association between anti-MTBD-tau autoantibodies and neurological diseases, which we categorized in 23 main groups of disorders. No associations between $\alpha\tau^+$ and neurological diseases were identified (Figure 4A). We further performed a targeted screen using plasma samples from 47 patients with AD and 68 similarly aged non-AD patients selected from our plasma biobank (eTable 1 in Supplement 1).

medRxiv preprint doi: https://doi.org/10.1101/2021.11.24.21266833; this version posted January 18, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

Samples were tested for anti-MTBD-tau IgG autoantibodies, as in the primary screen, and additionally for anti-MTBD-tau IgA autoantibodies and anti-full-length-tau IgG and IgA autoantibodies. No significant difference in reactivity was observed between the plasma samples from AD patients and non-AD controls (Figure 4B), supporting the hypothesis that the presence of autoantibodies targeting MTBD-tau is unrelated to AD or other neurological disorders.

Systemic disorders and anti-tau autoimmunity

We next assessed possible associations between tau autoimmunity and extraneural diseases, which we binned into 27 main groups of disorders (Figure 5A). After adjustment for multiple comparisons, $\alpha\tau$ immunoreactivity showed significant associations with vascular disorders (aRR 1.51, 95% CI 1.28-1.77, P<0.001), nutritional disorders (aRR 1.31, 95% CI 1.14-1.50, P<0.001), anemia (aRR 1.49, 95% CI 1.21-1.82, P<0.001), kidney disorders (aRR 1.27, 95% CI 1.10-1.45, P=0.001) and urinary disorders (aRR 1.40, 95%CI 1.20-1.63, P<0.001) (Figure 5A), whereas no association was observed among patients with autoimmune disorders (eFigure 5 in Supplement 1). There was no difference in the coincidence of all comorbidities between $\alpha\tau^+$ samples (5, 0.46%) and $\alpha\tau^-$ samples (69, 0.33%) (P=0.633).

To address potential biases arising from grouping and selecting major categories, we explored the association between $\alpha\tau^+$ and individual ICD-10 codes. Across 276 individual ICD-10 codes and after correction for multiple comparisons, eight exhibited significant associations with $\alpha\tau^+$ (Figures 5B and C). These included "E61–deficiency of other nutrient elements" (aRR 2.22, 95% CI 1.54-3.06, P<0.001), "I74–arterial embolism and thrombosis" (aRR 2.09, 95% CI 1.40-2.94, P<0.001), "N30–cystitis" (aRR 1.84, 95% CI 1.32-2.47, P<0.001), "I70–atherosclerosis" (aRR 1.57, 95% CI 1.29-1.89, P<0.001), "D50–iron deficiency anemia" (aRR 1.50, 95% CI 1.21-1.82, P<0.001), "N39–other urinary disorders" (aRR 1.40, 95% CI 1.19-1.64, P<0.001), "B96–other bacterial agents as the cause of diseases" (aRR 1.40, 95% CI 1.17-1.66, P<0.001) and "N18–chronic kidney disease" (aRR 1.38, 95% CI 1.18-1.60, P<0.001; Figure 5C). Conversely, we found no significant negative association between tau autoreactivity and any ICD-10 codes that could suggest a decreased risk for a specific disease in $\alpha\tau^+$ patients (Figure 5C). To verify relevant associations, we used Bayesian logistic regression using logit-transformed EC_{50} values (-logit[EC_{50}]) as a continuous outcome. All the previously referred eight ICD-10 codes showed positive associations with -logit[EC_{50}] (eFigure 6).

medRxiv preprint doi: https://doi.org/10.1101/2021.11.24.21266833; this version posted January 18, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

To validate these conditions as significant associations with plasma MTBD-tau IgG autoantibodies, we examined the association between $\alpha\tau^+$ and 106 commonly requested laboratory parameters using data available for 24,177 patients, independently of any ICD-10 classifiers. After correction for multiple comparisons, the laboratory markers "Leukocytes, urine", "Potassium" and "Urea" were positively associated with tau autoimmunity (Figure 5D). The association with increasing levels of urea and potassium suggests a link to kidney failure, whereas leukocytes in urine are a feature of urinary tract infections. These findings support the hypothesis that anti-tau autoimmunity correlates with such disorders. Accordingly, the prevalence of chronic kidney disease was 12.4% in $\alpha\tau^-$ and 17.7% in $\alpha\tau^+$ patients, whereas that of other urinary disorders was 10.3% in $\alpha\tau^-$ and 15.1% in $\alpha\tau^+$ patients (Figure 5E).

medRxiv preprint doi: https://doi.org/10.1101/2021.11.24.21266833; this version posted January 18, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

DISCUSSION

This study was designed to discover novel associations between autoreactivity to tau and human diseases. This approach of "reverse immunopathology" is hypothesis-free: it does not pose constraints on the type of diseases that might result from anti-tau immunity. While the approach is generally applicable to any autoantigen, its predictive power relies on the analysis of large patient collectives, which in turn requires the development of high-throughput methods at reasonable cost. We therefore miniaturized antibody detection to 3 µl/sample in 1,536-well microplates, allowing to run 40,000 assays/24 hrs with minimal hands-on time. We performed >300,000 immunoassays on >40,000 plasma samples for ατ autoreactivity.[23-25] Each sample was measured at eight dilution points, enabling precise and unambiguous titer determinations.[23-25].

Plasma ατ IgG were more prevalent in women and increased with age, reaching 7.6% in the cohort of 90-99-year-olds. The specificity of $\alpha\tau^+$ plasma to MTBD-tau was high and was confirmed by multiple assays including epitope mapping. The age- and sex-adjusted $\alpha\tau^+$ rate in hospital patients was three-fold higher than in healthy blood donors and was 2.4 times higher than that of autoantibodies targeting other intracellular neuronal targets, suggesting a correlation with disease states.[36] However, we did not find any association between $\alpha\tau^+$ and any neurological conditions including neurodegenerative diseases, corroborating with reports of similar levels of plasma tau autoantibodies in AD patients and non-demented controls.[37] Instead, we uncovered a robust, specific association between $\alpha\tau^+$ positivity and kidney and urinary disorders. This was independently validated by associations with higher prevalence of positive samples from the department of Nephrology, grouped kidney and urinary diseases, individual kidney and urinary diagnosis codes and related clinical laboratory biomarkers, such as high serum urea and potassium and high urine leukocytes.

Seroepidemiological studies cannot establish causality: ατ seropositivity could be a cause or a consequence of the clinical syndromes associated with it.[38] However, tau is expressed in extraneural tissues, including kidney podocytes and urinary bladder,[2-5] and its ablation causes glomerular pathologies.[39] Besides raising the possibility that plasma ατ autoantibodies might drive kidney pathologies, these findings suggest that such autoantibodies represent useful biomarkers of these diseases and that it will be important to monitor renal and urinary function in the current clinical trials of tau immunotherapy.[40-42]

medRxiv preprint doi: https://doi.org/10.1101/2021.11.24.21266833; this version posted January 18, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

Recent studies have explored the use of tau measurements in plasma as biomarkers for AD diagnosis and for monitoring its progression.[9-12,33,43-47] However, we found that anti-MTBD-tau autoantibodies could hinder tau detection in plasma by binding to epitopes recognized by commercial biomarker immunoassays. This aligns with prior research indicating that both plasma anti-tau autoantibodies and administered anti-tau antibodies can influence the dynamics of tau levels in plasma.[48] Additionally, a recent community cohort study using an immunoassay for AD screening revealed associations between plasma tau levels and numerous comorbidities, with chronic kidney disease showing one of the strongest associations.[49] These results imply that the presence of anti-tau autoantibodies in plasma might impact the effectiveness of plasma tau as an AD biomarker, particularly for patients with kidney or urinary diseases. This consideration may become crucial as plasma tau levels move toward routine clinical use in AD diagnosis.

Limitations

Our large-scale assessment of plasma tau autoimmunity has certain limitations. Firstly, most samples analyzed in our study came from a university hospital cohort, implying a bias towards complex pathologies and polymorbidities. To account for this, we included a vast collection of samples from healthy blood donors. Secondly, our study is confined to two sites within a single region with approximately 1,500,000 inhabitants whose ethnic composition was not thoroughly examined. Additionally, a direct comparison of the prevalence of plasma anti-tau antibodies in these two cohorts may potentially suffer from variations in materials, collection methods (e.g. addition of heparin that may cause aggregation of MTBD-tau), and handling processes at the two different sites. Thirdly, our study is restricted to the analysis of specific disease groups, the absence of a replication cohort and a longitudinal disease cohort that would allow for verification, examining a time course, origin, and causal role of these autoantibodies. Finally, we used bacterially expressed MTBD-tau as target, thereby excluding full-length or post-translationally modified tau epitopes. As a result, plasma anti-tau autoantibodies associated with AD pathology might be missed, and our methodology may underestimate the prevalence of total anti-tau autoantibodies.

Conclusions

medRxiv preprint doi: https://doi.org/10.1101/2021.11.24.21266833; this version posted January 18, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

Our study identified a high seroprevalence of anti-MTBD-tau IgG autoantibodies in both plasma samples from university hospital patients and healthy blood donors. Tau autoimmunity is associated with female sex, older age and previously unrecognized extraneural diseases. These findings point to unrecognized roles for tau and anti-tau autoantibodies in extraneural pathologies and call for attentive clinical monitoring of such diseases in clinical trials of tau-targeting therapies and in the use of plasma tau as a biomarker of disease.

medRxiv preprint doi: https://doi.org/10.1101/2021.11.24.21266833; this version posted January 18, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

References

1. Gu Y, Oyama F, Ihara Y. Tau is widely expressed in rat tissues. *J Neurochem*. Sep 1996;67(3):1235-44. doi:10.1046/j.1471-4159.1996.67031235.x
2. Uhlen M, Fagerberg L, Hallstrom BM, et al. Proteomics. Tissue-based map of the human proteome. *Science*. Jan 23 2015;347(6220):1260419. doi:10.1126/science.1260419
3. Sotiropoulos I, Galas MC, Silva JM, et al. Atypical, non-standard functions of the microtubule associated Tau protein. *Acta Neuropathol Commun*. Nov 2017;5(1):91. doi:10.1186/s40478-017-0489-6
4. Rinschen MM, Gödel M, Grahammer F, et al. A Multi-layered Quantitative In Vivo Expression Atlas of the Podocyte Unravels Kidney Disease Candidate Genes. *Cell Rep*. 05 2018;23(8):2495-2508. doi:10.1016/j.celrep.2018.04.059
5. Ho KH, Yang X, Osipovich AB, et al. Glucose Regulates Microtubule Disassembly and the Dose of Insulin Secretion via Tau Phosphorylation. *Diabetes*. Sep 2020;69(9):1936-1947. doi:10.2337/db19-1186
6. Kosik KS, Joachim CL, Selkoe DJ. Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. *Proc Natl Acad Sci U S A*. Jun 1986;83(11):4044-8. doi:10.1073/pnas.83.11.4044
7. Joachim CL, Morris JH, Kosik KS, Selkoe DJ. Tau antisera recognize neurofibrillary tangles in a range of neurodegenerative disorders. *Ann Neurol*. Oct 1987;22(4):514-20. doi:10.1002/ana.410220411
8. Hanseeuw BJ, Betensky RA, Jacobs HIL, et al. Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease: A Longitudinal Study. *JAMA Neurol*. Aug 1 2019;76(8):915-924. doi:10.1001/jamaneurol.2019.1424
9. Mattsson N, Zetterberg H, Janelidze S, et al. Plasma tau in Alzheimer disease. *Neurology*. Oct 25 2016;87(17):1827-1835. doi:10.1212/WNL.0000000000003246
10. Janelidze S, Mattsson N, Palmqvist S, et al. Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia. *Nat Med*. 03 2020;26(3):379-386. doi:10.1038/s41591-020-0755-1
11. Mielke MM, Hagen CE, Wennberg AMV, et al. Association of Plasma Total Tau Level With Cognitive Decline and Risk of Mild Cognitive Impairment or Dementia in the Mayo Clinic Study on Aging. *JAMA Neurol*. 09 01 2017;74(9):1073-1080. doi:10.1001/jamaneurol.2017.1359
12. Palmqvist S, Tideman P, Mattsson-Carlgren N, et al. Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care. *JAMA*. Jul 28 2024;doi:10.1001/jama.2024.13855
13. Congdon EE, Sigurdsson EM. Tau-targeting therapies for Alzheimer disease. *Nat Rev Neurol*. 07 2018;14(7):399-415. doi:10.1038/s41582-018-0013-z
14. Rothstein TL. Natural Antibodies as Rheostats for Susceptibility to Chronic Diseases in the Aged. *Front Immunol*. 2016;7:127. doi:10.3389/fimmu.2016.00127
15. Lutz HU, Binder CJ, Kaveri S. Naturally occurring auto-antibodies in homeostasis and disease. *Trends Immunol*. Jan 2009;30(1):43-51. doi:10.1016/j.it.2008.10.002
16. Jaycox JR, Dai Y, Ring AM. Decoding the autoantibody reactome. *Science*. Feb 16 2024;383(6684):705-707. doi:10.1126/science.abn1034

medRxiv preprint doi: https://doi.org/10.1101/2021.11.24.21266833; this version posted January 18, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

17. Florance NR, Davis RL, Lam C, et al. Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents. *Ann Neurol*. Jul 2009;66(1):11-8. doi:10.1002/ana.21756

18. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. *Lancet*. 2004 Dec 11-17 2004;364(9451):2106-12. doi:10.1016/S0140-6736(04)17551-X

19. Ferrero J, Williams L, Stella H, et al. First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's disease. *Alzheimers Dement (N Y)*. Sep 2016;2(3):169-176. doi:10.1016/j.trci.2016.06.002

20. Bartos A, Fialová L, Švarcová J. Lower Serum Antibodies Against Tau Protein and Heavy Neurofilament in Alzheimer's Disease. *J Alzheimers Dis*. 2018;64(3):751-760. doi:10.3233/JAD-180039

21. Kronimus Y, Albus A, Balzer-Geldsetzer M, et al. Naturally Occurring Autoantibodies against Tau Protein Are Reduced in Parkinson's Disease Dementia. *PLoS One*. 2016;11(11):e0164953. doi:10.1371/journal.pone.0164953

22. Bartos A, Fialova L, Svarcova J. Lower Serum Antibodies Against Tau Protein and Heavy Neurofilament in Alzheimer's Disease. *J Alzheimers Dis*. 2018;64(3):751-760. doi:10.3233/JAD-180039

23. Emmenegger M, De Cecco E, Lamparter D, et al. Continuous population-level monitoring of SARS-CoV-2 seroprevalence in a large European metropolitan region. *iScience*. Feb 17 2023;26(2):105928. doi:10.1016/j.isci.2023.105928

24. Senatore A, Frontzek K, Emmenegger M, et al. Protective anti-prion antibodies in human immunoglobulin repertoires. *EMBO Mol Med*. Sep 7 2020;12(9):e12739. doi:10.15252/emmm.202012739

25. Emmenegger M, Zografou C, Yile D, et al. The Cystic Fibrosis Transmembrane Regulator Controls Tolerogenic Responses to Food Allergens in Mice and Humans. *medRxiv*. 2024;doi:https://doi.org/10.1101/2024.06.17.24309019

26. Organization WH. ICD-10 : international statistical classification of diseases and related health problems : tenth revision, 2nd ed. World Health Organization. https://iris.who.int/handle/10665/42980. 2004.

27. de Silva R, Lashley T, Gibb G, et al. Pathological inclusion bodies in tauopathies contain distinct complements of tau with three or four microtubule-binding repeat domains as demonstrated by new specific monoclonal antibodies. *Neuropathol Appl Neurobiol*. Jun 2003;29(3):288-302. doi:10.1046/j.1365-2990.2003.00463.x

28. McNutt LA, Wu C, Xue X, Hafner JP. Estimating the relative risk in cohort studies and clinical trials of common outcomes. *Am J Epidemiol*. May 2003;157(10):940-3. doi:10.1093/aje/kwg074

29. Diaz-Quijano FA. A simple method for estimating relative risk using logistic regression. *BMC Med Res Methodol*. Feb 2012;12:14. doi:10.1186/1471-2288-12-14

30. *RStudio: Integrated Development Environment for R*. RStudio, PBC; 2021.

31. Donoghoe MW, Marschner IC. Logbin: An R Package for Relative Risk Regression Using the Log-Binomial Model. *Journal of Statistical Software* 2018;86(21)

32. Apetri A, Crespo R, Juraszek J, et al. A common antigenic motif recognized by naturally occurring human V. *Acta Neuropathol Commun*. 05 2018;6(1):43. doi:10.1186/s40478-018-0543-z

medRxiv preprint doi: https://doi.org/10.1101/2021.11.24.21266833; this version posted January 18, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

33. Pase MP, Beiser AS, Himali JJ, et al. Assessment of Plasma Total Tau Level as a Predictive Biomarker for Dementia and Related Endophenotypes. *JAMA Neurol*. 05 2019;76(5):598-606. doi:10.1001/jamaneurol.2018.4666

34. Barini E, Plotzky G, Mordashova Y, et al. Tau in the brain interstitial fluid is fragmented and seeding-competent. *Neurobiol Aging*. Jan 2022;109:64-77. doi:10.1016/j.neurobiolaging.2021.09.013

35. Donoghoe MW, Marschner IC. logbin: An R Package for Relative Risk Regression Using the Log-Binomial Model. *Journal of Statistical Software*. Sep 4, 2018 2018;86(9):21. doi:10.18637/jss.v086.i09

36. Dahm L, Ott C, Steiner J, et al. Seroprevalence of autoantibodies against brain antigens in health and disease. *Ann Neurol*. Jul 2014;76(1):82-94. doi:10.1002/ana.24189

37. Yu G, Chen J, Xu Y, et al. Generation of goats lacking prion protein. *Mol Reprod Dev*. Jan 2009;76(1):3. doi:10.1002/mrd.20960

38. Tsuboi Y, Uitti RJ, Delisle MB, et al. Clinical features and disease haplotypes of individuals with the N279K tau gene mutation: a comparison of the pallidopontonigral degeneration kindred and a French family. *Arch Neurol*. Jun 2002;59(6):943-50. doi:10.1001/archneur.59.6.943

39. Vallés-Saiz L, Peinado-Cahuchola R, Ávila J, Hernández F. Microtubule-associated protein tau in murine kidney: role in podocyte architecture. *Cell Mol Life Sci*. Jan 27 2022;79(2):97. doi:10.1007/s00018-021-04106-z

40. Congdon EE, Ji C, Tetlow AM, Jiang Y, Sigurdsson EM. Tau-targeting therapies for Alzheimer disease: current status and future directions. *Nat Rev Neurol*. Dec 2023;19(12):715-736. doi:10.1038/s41582-023-00883-2

41. NCT05269394 ClinicalTrial.gov, NCT05269394, Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU), (https://clinicaltrials.gov/study/NCT05269394?cond=Alzheimer%20Disease&term=E2814&rank=1) (2023).

42. Barton ME, Van Den Steen B, Van Tricht HLG, et al. Update on the TOGETHER study: a patient- and investigator-blind, randomized, placebo-controlled study evaluating the efficacy, safety and tolerability of bepranemab, UCB0107, in prodromal-to-mild Alzheimer’s disease. *Alzheimer's & Dementia*. 2022;18(S10):e068973.

43. Moscoso A, Grothe MJ, Ashton NJ, et al. Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease. *JAMA Neurol*. Apr 01 2021;78(4):396-406. doi:10.1001/jamaneurol.2020.4986

44. Barthélemy NR, Li Y, Joseph-Mathurin N, et al. A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease. *Nat Med*. 03 2020;26(3):398-407. doi:10.1038/s41591-020-0781-z

45. Karikari TK, Pascoal TA, Ashton NJ, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. *Lancet Neurol*. 05 2020;19(5):422-433. doi:10.1016/S1474-4422(20)30071-5

medRxiv preprint doi: https://doi.org/10.1101/2021.11.24.21266833; this version posted January 18, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

46. Park JC, Han SH, Yi D, et al. Plasma tau/amyloid-β1-42 ratio predicts brain tau deposition and neurodegeneration in Alzheimer's disease. *Brain*. 03 01 2019;142(3):771-786. doi:10.1093/brain/awy347

47. Palmqvist S, Janelidze S, Quiroz YT, et al. Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. *JAMA*. Aug 25 2020;324(8):772-781. doi:10.1001/jama.2020.12134

48. Yanamandra K, Patel TK, Jiang H, et al. Anti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy. *Sci Transl Med*. 04 2017;9(386)doi:10.1126/scitranslmed.aal2029

49. Mielke MM, Dage JL, Frank RD, et al. Performance of plasma phosphorylated tau 181 and 217 in the community. *Nat Med*. Jul 2022;28(7):1398-1405. doi:10.1038/s41591-022-01822-2

Acknowledgments:

The authors wish to thank the hospital patients and blood donors for their generous altruistic contributions to this study. Imaging was performed with equipment maintained by the Center for Microscopy and Image Analysis, University of Zurich. We thank Prof. Rohan de Silva (UCL Queen Square Institute of Neurology, London, UK) for providing the purified anti-MTBD-tau antibody RD4. We thank Dr. Marco Losa. Magdalena Bialkowska, Lisa Caflisch, Berre Doğançay, Julie Domange, Marigona Imeri, Lorène Mottier, Rea Müller, Antonella Rosati, Dezirae Schneider, and Anne Wiedmer for help with the high-throughput assays. Insightful advice about programming in R software was provided by Reto Guadagnini. Imaging was performed with equipment from the Center for Microscopy and Image Analysis, University of Zurich.

Funding:

University of Zürich, Candoc grant FK-19-025 (ADM)

Swiss Personalised Health Network, SPHN, driver project grant 2017DRI17 (AA)

Swiss National Foundation SNF (SNSF grant ID 179040 and grant ID 207872, Sinergia grant ID 183563) (AA)

European Research Council ERC Prion2020, 670958 (AA)

Nomis Foundation (AA)

Innovation Fund of the University Hospital Zurich (INOV00096) (AA)

University Hospital Zurich Foundation grant USZF27101 (with contributions of the NOMIS Foundation, the Schwyzer Winiker Stiftung, and the Baugarten Stiftung, AA, ME)

medRxiv preprint doi: https://doi.org/10.1101/2021.11.24.21266833; this version posted January 18, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

HMZ ImmunoTarget grant, Stiftung Neuropath and GELU Foundation (AA)
Michael J. Fox Foundation (grant ID MJFF-020710 and MJFF-021073) (SH).

Author contributions:

Conceived and designed the experiments: ADM, SH, AA. Supervised the study: SH, AA. Performed tau protein purification: ADM, EDC, JG. Performed tau microELISA automated screen: ADM, ME. Performed amyloid-ß pyroglutamate and cellular prion protein microELISA automated screen: MC, KF, ME. Maintained microELISA automated platform: ME. Performed purification, validation and characterization of anti-tau autoantibodies: ADM, JG. Maintained the clinical database: ME, AC. Performed data analysis and visualization: ADM. Wrote the first draft of manuscript: ADM. Corrected and advised on subsequent versions of the manuscript: ADM, ME, SH, AA. All authors reviewed and approved the final version of the manuscript and consented to be accountable for the work.

Competing interests:

ADM has received a research grant from University of Zurich; KF has received research grants from Ono Pharmaceuticals and Theodor Ida Herzog Egli Stiftung, consulting fees from Acumen Collective and Ionis Pharmaceuticals, support for attending meetings/travel from Euro-CNS and has participated on the Advisory Board of Mabylon AG; AA has received research grants from the Swiss Personalized Health Network, Swiss National Foundation, European Research Council and Nomis Foundation and is a member of the Board of Directors of Mabylon AG. Mabylon AG produces therapeutic human antibodies. Mabylon AG had no insight and no influence on the current study. All authors report no other relationships or activities that could appear to have influenced the submitted work.

Data and materials availability:

Data and materials will be shared upon approval by the Cantonal Ethics Committee where necessary.

medRxiv preprint doi: https://doi.org/10.1101/2021.11.24.21266833; this version posted January 18, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

Figures



Figure 1. Study overview and seroprevalence of anti-MTBD-tau IgG autoantibodies. A. Flowchart of the study design. **B.-C.** Distribution of -$\log_{10}(EC_{50})$ values obtained from the micro-ELISA screen of hospital (B) and blood donor (C) plasma samples. **D.** aRR and 95% CI (I bars) for the detection of anti-tau autoantibodies in hospital and blood-bank plasma samples. **E.** Replicability of microELISA duplicates with independent estimation of the -$\log_{10}(EC_{50})$ values. Dashed lines: cut-off value of -$\log_{10}(EC_{50})$ = 1.8. **F.** -$\log_{10}(EC_{50})$ values of samples tested by microELISA against MTBD-tau and amyloid-ß pyroglutamate. **G.** Same as shown in (F), but for samples tested against MTBD-tau and PrP^{C}.

medRxiv preprint doi: https://doi.org/10.1101/2021.11.24.21266833; this version posted January 18, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .



Figure 2. Natural ατ autoantibodies impair tau detection. A. Principle of the competition sandwich ELISA. **B-C.** Competitive sandwich ELISA to assess the ability of purified anti-tau autoantibodies with matching (P4-P6) and non-matching (P2 and P3) epitopes to the commercial detection antibody, ab64193, to impair the detection of free tau^{441} spiked in plasma (dark blue). Serial dilutions of purified anti-tau antibodies are shown in (B) and binding at highest anti-tau antibody concentrations in (C).

medRxiv preprint doi: https://doi.org/10.1101/2021.11.24.21266833; this version posted January 18, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .



Figure 3. Demographic characteristics of hospital patients' cohort. A. Age and sex pyramid of positive and negative individuals. **B.** Percentage of positives among hospital patients across decadic age groups. The numbers on top of each bar correspond to the positivity rates. χ^2 test for trend in proportions. **C.** RR ± 95% CI for $\alpha\tau^+$ autoantibodies according to sex and age groups. Asterisks: $P < 0.05$ after Bonferroni correction. **D.** Break-down of samples by clinical department. Asterisks: $P < 0.05$ (two-proportions z-test with Bonferroni correction). **E.** aRR ± 95% CI for $\alpha\tau^+$ samples by clinical department. Asterisks: $P < 0.05$ after Bonferroni correction.

medRxiv preprint doi: https://doi.org/10.1101/2021.11.24.21266833; this version posted January 18, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .



Figure 4. aRR of MTBD-tau-autoreactivity for major groups of neurological disorders and reactivity profiles for AD screen. **A.** aRR and 95% CI (I bars) for $\alpha\tau^{+}$ autoantibodies according to different groups of neurological disorders. No P values remained significant after Bonferroni correction. **B.** Boxplots showing the 25th, 50th (median) and 75th percentiles of the reactivity profiles for AD and control patients (Mann-Whitney U test).

medRxiv preprint doi: https://doi.org/10.1101/2021.11.24.21266833; this version posted January 18, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .



Figure 5. Association of MTBD-tau IgG autoantibodies with systemic disorders and clinical laboratory data. A. aRR ± 95% CI (bars) for $\alpha\tau^+$ autoantibodies grouped 27 different main systemic clinical conditions. Asterisks: $P < 0.05$ after Bonferroni correction. **B.** $-\log_{10}$(P value) of the log-binomial regression for the presence of plasma MTBD-tau IgG autoantibodies for 276 disorders according to ICD-10 codes and adjusted for age and sex. Triangles pointing upwards and downwards: positive and coefficients, respectively; gray dashed line: $P < 0.05$ after Bonferroni correction (here and henceforth). P values significant after Bonferroni adjustment are labelled with the ICD codes. **C**. Bayesian logistic regression adjusted for age and sex on ICD-10 codes significantly associated in B. and using $-\text{logit}_{10}(EC_{50})$ as continuous outcome (odds ratio ± 95% credible

medRxiv preprint doi: https://doi.org/10.1101/2021.11.24.21266833; this version posted January 18, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

intervals). This analysis confirms the positive association of these ICD-10 codes with ατ reactivity (from B). **D.** -$\log_{10}$(P value) of the log-binomial regression for the presence of plasma MTBD-tau IgG autoantibodies and clinical laboratory parameters. P values significant after Bonferroni adjustment are labelled with the ICD codes. The gray dashed line indicates the significance level after Bonferroni correction (<0.05/106=0.00047). eGFR CKD-EPI 2009: estimated glomerular filtration rate using the Chronic Kidney Disease Epidemiology Collaboration 2009 equation; eGFR BIS1: estimated glomerular filtration rate using the older adults Berlin Initiative Study 1 equation. INR: international normalized ratio. LDL: low-density lipoprotein. HDL: high-density lipoprotein. **E.** Calculated prevalence of different ICD-10 codes in the total cohort (dark blue), $\alpha\tau^-$ (intermediate blue) and $\alpha\tau^+$ samples (light blue).